Fezakinumab
- Generic Name
- Fezakinumab
- Drug Type
- Biotech
- CAS Number
- 1007106-86-6
- Unique Ingredient Identifier
- 0S77U25XZ3
- Background
Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 60
- Registration Number
- NCT01941537
- Locations
- ๐บ๐ธ
The Rockefeller University, New York, New York, United States
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 195
- Registration Number
- NCT00883896
- Locations
- ๐บ๐ธ
Deaconess Hospital, Cincinnati, Ohio, United States
๐ง๐ชChu Liege Sart Tilman B 35, Liege, Belgium
๐บ๐ธClinical Research Advantage, Inc., Sarasota, Florida, United States
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00563524
- Locations
- ๐บ๐ธ
Hudson Dermatology, Evansville, Indiana, United States
๐บ๐ธDawes Fretzin Clinical Research Group, Indianapolis, Indiana, United States
๐บ๐ธBaylor Research Institute, Dallas, Texas, United States
Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT00447681
Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT00434746
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath